2024 Year in Review: Reflecting on Progress and Innovation at Eurofins Viracor
As we look back on 2024, Eurofins Viracor continues to solidify its position as a leader in diagnostic testing for critical patients. With over 40 years of experience, we have become an authoritative voice in diagnostics, monitoring, and guiding informed therapeutic decisions. Our expertise, honed over decades of dedicated service, ensures the delivery of accurate, reliable results across thousands of tests, all while maintaining exceptional turnaround times. We remain steadfast in our commitment to providing timely insights and support, ensuring that healthcare providers can rely on us for the information they need to make key decisions.
Our dedication to advancing diagnostics is at the core of our mission, positioning us at the forefront of medical testing innovation. By incorporating cutting-edge technologies and research into our processes, we continuously expand our capabilities to meet the evolving needs of healthcare professionals, improving patient outcomes with each new advancement.
New Assays Launched in 2024
In 2024, Eurofins Viracor introduced several groundbreaking clinical assays designed to elevate diagnostic accuracy and improve patient outcomes. These innovations enhance our ability to support clinicians in making informed decisions quickly, particularly for complex and time-sensitive cases.
NeXGen™ Fungal / AFB NGS Assay
The NeXGen™ Fungal / AFB NGS assay employs advanced next-generation sequencing to detect fungal pathogens and acid-fast bacteria with unmatched precision. This high-throughput, non-invasive test delivers rapid and accurate identification of a wide range of microorganisms, allowing for timely clinical decision-making in the management of complex infections. By offering comprehensive analysis, NeXGen NGS helps healthcare providers understand these infections better, guiding targeted therapeutic strategies that improve patient outcomes.
TTViWATCH Torque Teno Virus Viral Load Monitoring Assay
The TTViWATCH assay utilizes quantitative PCR to precisely detect Torque Teno Virus (TTV) viral load, providing vital insights into the immune status of immunocompromised patients. This highly sensitive assay is especially valuable for clinicians managing patients undergoing transplant or cancer therapies. By offering timely and accurate results, the TTViWATCH assay enables early detection of potential complications and supports personalized treatment strategies, optimizing patient care.
TA-TMA Comprehensive Assays
The TA-TMA Comprehensive assays provide clinicians with a complete and thorough assessment of complement pathway regulation and potential deregulation, including validated assays for Eculizumab, CH50, and sC5b-9. Our all-encompassing approach ensures detailed results across three critical areas, empowering clinicians to make informed treatment decisions without delay. With our industry-leading 24-hour turnaround times, these tests play a crucial role in monitoring complement activity and managing transplant-associated thrombotic microangiopathy, as well as complement-mediated diseases, ultimately helping to optimize patient management and treatment strategies.
Other notable additions include the Mycobacterium avium and M. abscessus RT-PCR tests, enabling faster and more accurate identification of these challenging pathogens in immunocompromised patients. We also added to the Mucorales Real-Time PCR, a vital tool for detecting Mucorales fungi in patients at risk for invasive mucormycosis, and the CAR T Persistence Exception, which provides important insights into the persistence of CAR T-cell therapies. Additionally, the Fungal Plus I & Fungal Plus II profile panels and Mucorales PCR offer broader fungal infection detection, while the Nocardia Real-Time PCR test strengthens our ability to identify Nocardia infections in a timely manner. Finally, the RealTime HCV Genotype tests enhances our understanding of hepatitis C virus mutations, facilitating more personalized and effective treatment strategies. These advancements reflect our commitment to providing cutting-edge diagnostic tools for improved patient outcomes
Continued Commitment to Excellence & Innovation
At Eurofins Viracor, we continue to revolutionize diagnostic testing through cutting-edge innovations that improve both the speed and accuracy of patient care. Our assays are thoughtfully designed to meet a wide range of clinical needs, including those emerging from new and evolving therapies. By leveraging advanced technologies, we are able to offer comprehensive solutions that not only support healthcare professionals but also significantly improve patient outcomes.
We invite you to explore how our pioneering assays can enhance your clinical practice and patient care. Explore our website to learn more about these transformative innovations in diagnostic testing.
Trust Eurofins Viracor for accurate results, exceptional turnaround times, and personalized guidance that empowers informed healthcare decisions. We’re improving lives, one test at a time.